Pam Swiggard
- Role
- Vice President Regulatory Affairs at Palvella Therapeutics
- Location
- Wayne, PA, US
- LinkedIn followers
- 500 followers
About Pam Swiggard
Pharmaceutical executive with broad depth of regulatory expertise and breadth of…
Experience
Vice President Regulatory Affairs
Oct 2020 — Present
Palvella Therapeutics is a late clinical-stage biopharmaceutical company whose vision is to become the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Our versatile QTORIN platform is designed to generate new therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of rare skin diseases. Our lead product candidate, QTORIN rapamycin, is in clinical development for three genetic skin diseases: pachyonychia congenita, microcystic lymphatic malformations, and basal cell carcinomas in Gorlin syndrome patients. We have three ongoing clinical trials, including VAPAUS, our randomized, double-blind, Phase 3 clinical trial for the treatment of pachyonychia congenita.
Education
Temple University
MS, QA/RA
2001 — 2003
Penn State University
BS, Microbiology
1985 — 1989
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.